A Health Economist to lead the NIH

By SAURABH JHA Early on in the COVID-19 pandemic a seroprevalence study from Santa Clara indicated that the viral spread was far greater than was believed. The study suggested that the infection fatality rate (IFR) was much lower than the case fatality rate and perhaps even lower than the suspected IFR. The researchers estimated that…

Read More

How many patients are switching to biosimilars?

That is a key question if long-run drug prices are going to come down for biologic products. We can decompose this question into 3 sub-questions: What share patients initiating therapy start on a biosimilar?What share of patients already using a biologic products switch to a biosimilar?Do patient of physician factors drive biosimilar prescribing patterns? A…

Read More